Device Transactions Thirty-six financings brought in $1.2 billion during 2013’s fourth quarter, almost double Q3’s $644 million total, making it the most lucrative quarter of 2013. The majority (63%)
IN VITRO DIAGNOSTICS Alliances Almac Group Ltd. Almac Diagnostics Genomic Health Inc. Genomic Health Inc. licensed rights to fellow cancer testing company Almac Diagnostics ’ technology and IP